PE20120774A1 - COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1 - Google Patents

COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1

Info

Publication number
PE20120774A1
PE20120774A1 PE2011001707A PE2011001707A PE20120774A1 PE 20120774 A1 PE20120774 A1 PE 20120774A1 PE 2011001707 A PE2011001707 A PE 2011001707A PE 2011001707 A PE2011001707 A PE 2011001707A PE 20120774 A1 PE20120774 A1 PE 20120774A1
Authority
PE
Peru
Prior art keywords
thiazol
dioxo
pyrimidin
acetamide
hydroxyl
Prior art date
Application number
PE2011001707A
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sachin Vasantrao Dhone
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Nisha Parag Patil
Ashok Bhausaheb Kadam
Vishal Govindrao Deshmukh
Rajendra Prakash Chikhale
Sachin Sundarlal Chaudhari
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20120774A1 publication Critical patent/PE20120774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 Y R2 SON CADA UNO H, HIDROXILO, ALQUILO, HALOALQUILO, ENTRE OTROS; Rb ES H, HIDROXILO, CIANO, HALOGENO, HALOALQUILO, ENTRE OTROS; U ES ARILO OPCIONALMENTE SUSTITUIDO, HETEROCICLOS C5 TALES COMO TIAZOL, IMIDAZOL, ISOXAZOL, PIRAZOL, TIADIAZOL, PIRIMIDINA O BENZOTIAZOL; V ES H, CIANO, NITRO, -NRXRY, HALOGENO, ENTRE OTROS; RX Y RY SON H, HIDROXILO, HALOGENO, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(2,4-DIFLUOROFENIL)-1,3-TIAZOL-2-IL]-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRA HIDRO-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ACETAMIDA; 2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDRO-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)-N-{4-[4-FLUORO-3-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-2-IL} ACETAMIDA; 2-(4,6-DIMETIL-5,7-DIOXO-4,5,6,7-TETRAHIDRO-1H-PIRAZOLO [4,3-d]PIRIMIDIN-1-IL)-N-{4-[3-FLUORO-4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-2-IL} ACETAMIDA; ENTRE OTROS. DICHO COMPUESTO ES UN DERIVADO DE PIRIMIDINDIONA FUSIONADO MODULADOR DEL RECEPTOR DE POTENCIAL TRANSITORIO DE LA SUBFAMILIA A, MIEMBRO 1 (TRPA1) UTILES PARA TRATAR O PREVENIR UNA ENFERMEDAD RELACIONADA CON TRPA1
PE2011001707A 2009-03-23 2010-03-17 COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1 PE20120774A1 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2212MU2009 2009-09-23
IN2211MU2009 2009-09-23
US25194409P 2009-10-15 2009-10-15
US25326309P 2009-10-20 2009-10-20
IN2892MU2009 2009-12-15
IN2891MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US30024110P 2010-02-01 2010-02-01

Publications (1)

Publication Number Publication Date
PE20120774A1 true PE20120774A1 (es) 2012-06-27

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001707A PE20120774A1 (es) 2009-03-23 2010-03-17 COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1

Country Status (24)

Country Link
US (1) US9000159B2 (es)
EP (2) EP2708538B1 (es)
JP (1) JP5657638B2 (es)
KR (1) KR20110132575A (es)
CN (1) CN102361873B (es)
AP (1) AP3280A (es)
AU (1) AU2010227245B2 (es)
BR (1) BRPI1013559A2 (es)
CA (1) CA2756518A1 (es)
CL (2) CL2011002315A1 (es)
DK (1) DK2411393T3 (es)
EA (1) EA023857B1 (es)
ES (2) ES2456515T3 (es)
HK (2) HK1166075A1 (es)
IL (1) IL215178A (es)
MX (1) MX2011009824A (es)
PE (1) PE20120774A1 (es)
PL (1) PL2411393T3 (es)
PT (1) PT2411393E (es)
SG (1) SG174402A1 (es)
SI (1) SI2411393T1 (es)
UA (1) UA108069C2 (es)
WO (1) WO2010109287A1 (es)
ZA (1) ZA201107648B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281747B2 (en) 2006-08-07 2013-11-07 Ironwood Pharmaceuticals, Inc. Indole compounds
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体
CA2820448A1 (en) * 2010-12-20 2012-06-28 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CA2836856A1 (en) 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
US20140107113A1 (en) 2011-06-22 2014-04-17 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
US20140148423A1 (en) 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
RU2014108885A (ru) 2011-08-09 2015-09-20 Хайдра Байосайенсиз, Инк. Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
WO2013084153A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
WO2013108857A1 (ja) 2012-01-17 2013-07-25 味の素株式会社 複素環アミド誘導体及びそれを含有する医薬
CN104350058A (zh) 2012-06-08 2015-02-11 格兰马克药品股份有限公司 2-氨基-4-芳基噻唑化合物的酰胺及其盐
MY187910A (en) 2012-10-01 2021-10-28 Orion Corp N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
EP3057583A2 (en) 2013-10-15 2016-08-24 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MX2016005142A (es) * 2013-10-30 2016-10-28 Shanghai hengrui pharmaceutical co ltd Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN109983017B (zh) * 2017-07-28 2021-11-12 江苏恒瑞医药股份有限公司 一种嘧啶酮并杂芳基类衍生物的制备方法及其中间体
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
MX2024009581A (es) * 2022-02-03 2024-08-13 D E Shaw Res Llc Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN118373832A (zh) * 2023-01-20 2024-07-23 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
JP2007522214A (ja) 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
TWI610684B (zh) * 2005-12-22 2018-01-11 海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2009158719A2 (en) * 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
SG184767A1 (en) 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AU2010261888A1 (en) 2009-06-18 2012-01-19 Basf Se Fungicidal mixtures
WO2011045702A1 (en) 2009-10-15 2011-04-21 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR101265451B1 (ko) 2010-07-13 2013-05-22 노파르티스 아게 옥사진 유도체, 및 신경계 장애의 치료에 있어서의 그의 용도

Also Published As

Publication number Publication date
US20140128603A1 (en) 2014-05-08
IL215178A0 (en) 2011-12-29
JP2012521401A (ja) 2012-09-13
CL2011002315A1 (es) 2012-04-09
MX2011009824A (es) 2012-01-25
AP2011005887A0 (en) 2011-10-31
AU2010227245A2 (en) 2011-10-27
ZA201107648B (en) 2012-07-25
UA108069C2 (uk) 2015-03-25
SG174402A1 (en) 2011-10-28
HK1166075A1 (en) 2012-10-19
EP2708538B1 (en) 2015-08-12
IL215178A (en) 2015-01-29
EP2411393A1 (en) 2012-02-01
US9000159B2 (en) 2015-04-07
AU2010227245A1 (en) 2011-09-22
AU2010227245B2 (en) 2015-09-10
BRPI1013559A2 (pt) 2016-04-12
EA201190143A1 (ru) 2012-04-30
EP2411393A4 (en) 2012-08-01
CN102361873B (zh) 2014-07-09
CN102361873A (zh) 2012-02-22
AP3280A (en) 2015-05-31
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
KR20110132575A (ko) 2011-12-08
ES2456515T3 (es) 2014-04-22
EP2411393B1 (en) 2014-01-22
CA2756518A1 (en) 2010-09-30
CL2014001447A1 (es) 2014-10-17
HK1194742A1 (en) 2014-10-24
PT2411393E (pt) 2014-02-21
PL2411393T3 (pl) 2014-06-30
JP5657638B2 (ja) 2015-01-21
ES2551085T3 (es) 2015-11-16
SI2411393T1 (sl) 2014-03-31
EP2708538A1 (en) 2014-03-19
WO2010109287A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
PE20120774A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1
PE20120775A1 (es) Derivados de tienopirimidindiona como moduladores de trpa1
AR114667A2 (es) Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
PE20120764A1 (es) Derivados de isotiazolo-pirimidindiona como moduladores de trpa1
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20140234A1 (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20180175A1 (es) Nuevos derivados de imidazolilmetilo 5-sustituidos
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
RU2014124953A (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20120304A1 (es) Derivados de 1,3-tiazolidina-2,4-diona con actividad sobre quinasas pim-1 y/o pim-2 y/o pim-3
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
AR044163A1 (es) Derivados de pirazol sustituidos, composiciones farmaceuticas que los contienen y compuestos relacionados como antagonistas del receptor de bradiquinina b1
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
JP2016516026A5 (es)
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20160666A1 (es) Derivados de etinilo
AR050557A1 (es) Compuestos heterociclicos sustituidos y sus usos
JP2013538802A5 (es)
NZ629636A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
RU2010143455A (ru) Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed